<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20190219042766N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2019-09-28</date_registration>
      <primary_sponsor>Esfahan University of Medical Sciences</primary_sponsor>
      <public_title>Extubation method on extubation failure and mechanical ventilation duration</public_title>
      <acronym></acronym>
      <scientific_title>Comparision of two methods according to clinical judgment  and protocol in extubation on mechanical ventilation duration and extubation failure in children</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2019-06-27</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>68</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/37671</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Block randomization with two numbers in each block.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Extubation method.</hc_freetext>
      <i_freetext>Intervention 1: In intervention group,the readiness criteria included the  following are evaluated: recovery or eliminating  of their underlying causes for respiratory failure and intubation, T&lt;38.5 ºC,  HB&gt; 8, ability to swallow secretions, having gag or cough reflexes during suctioning the secretions, having an acceptable level of consciousness, i.e. GCS score≥8 after discontinuing sedations and analgesics, correction of electrolytes, absence of new findings in the chest X-ray, no needs for increasing the settings of  the ventilator over the previous 24 hours, the total discontinuation of sedations and analgesics in at least the previous six hours, no needs for vasoactive agents, an acceptable arterial-blood gas and air exchange with StO2&gt;94% despite FiO2&lt;40, PIP&lt;20 and PEEP&lt;5.If they meet all criteria,  the ventilator settings are set as follows: Mode: Spont/PSV, PEEP≤5, FiO2≤40, PS according to ET size (3-3.5:10, 4-4.5:8, ≥5:6). The SBT failure is confirmed in case at least two of the following conditions are observed during the intervention: respiratory rate being outside the normal range by age, i.e. tachypnea or bradypnea, respiratory distress, VTe&lt;5 ml/kg, SatO2&lt;90%, hypotension based on PALS guidelines or an over 20% increase in blood pressure, impaired consciousness associated with hypoventilation, heart rate outside the normal range by age, i.e. tachycardia and bradycardia, Pco2&gt;55 mmHg or an increase in Pco2 by at least 10mmHg in patients with chronic pulmonary disease in the final arterial-blood gas test. If the test failed, the parameters and mode of the ventilator are set as before the test, and if the clinical criteria are met as described, the test is repeated 24 hours later.Endotracheal  tube is immediately extracted if the test is successful, and the patient is provided with a non-rebreathing face mask with a 10-15 l/min flow, and undergo100% oxygen therapy. Arterial-blood gas test is performed two hours after extubation. Extubation failure is confirmed in case at least two of the following symptoms emerged within two days of extubation: respiratory distress, hypoxia with SatO2&lt;90%, respiratory rate outside the normal range by age, i.e. tachypnea or bradypnea , apnea&gt;20 seconds, hypotension based on PALS guidelines or an over 20% increase in blood pressure, impaired consciousness associated with hypoventilation, heart rate outside the normal range by age, i.e. tachycardia and bradycardia, Pco2&gt;55 mmHg or an increase in Pco2 by at least 10mmHg in patients with chronic pulmonary disease accompanied by PH&lt;7.3 and symptoms of upper airway obstruction. In case of the absence of contraindications for NIMV, Bi-level positive airway pressure (BiPAP) is applied with minimum settings as EPAP:5 and IPAP:8-10, and tittered up to EPAP:8-10 and IPAP:5-22 and until clinical and laboratory symptoms of respiratory failure disappear. The patient is reintubated if respiratory failure symptoms persist after two hours of monitoring. Intervention 2: In control group ,The attendant of pediatric or anesthesiology by ICU fellowship decides on ventilator settings and respiratory support reduction and extubation according to the results of arterial-blood gas tests performed at least once a day and based on the patient's clinical conditions, including eliminating the causes of intubation, appropriate ventilation and oxygenation and stable vital signs.The post-extubation oxygen supply method, the criteria of extubation failure and NIMV and reintubation protocols are as same as the intervention group.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is Making decision after doing this study.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr Atefeh Sadeghizadeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Kilometer 10 Imam Khomeini Avenue- Imam Hussein Hospital</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۸۱۹۵۱۶۳۳۸۱</zip>
        <telephone>+98 31 3386 6266</telephone>
        <email>a.sadeghizadeh@gmail.com</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr atefeh Sadeghizadeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Kilometer 10 Imam khomeini Avenue,Imam Hussein Hospital</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۸۱۹۵۱۶۳۳۸۱</zip>
        <telephone>+98 31 3386 6266</telephone>
        <email>a.sadeghizadeh@gmail.com</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>All infants and children ،aged between 1 month to 14 years، admitted in PICU
Patients have been receiving MV above 12 hours</inclusion_criteria>
      <agemin>1 month</agemin>
      <agemax>14 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Intubation due to upper airway obstruction (UAO)
neuromuscular disease
tracheostomy
chronic MV use
cyanotic congenital heart disease
primary pulmonary hypertension.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>N/A</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>In intervention group,the readiness criteria included the  following are evaluated: recovery or eliminating  of their underlying causes for respiratory failure and intubation, T&lt;38.5 ºC,  HB&gt; 8, ability to swallow secretions, having gag or cough reflexes during suctioning the secretions, having an acceptable level of consciousness, i.e. GCS score≥8 after discontinuing sedations and analgesics, correction of electrolytes, absence of new findings in the chest X-ray, no needs for increasing the settings of  the ventilator over the previous 24 hours, the total discontinuation of sedations and analgesics in at least the previous six hours, no needs for vasoactive agents, an acceptable arterial-blood gas and air exchange with StO2&gt;94% despite FiO2&lt;40, PIP&lt;20 and PEEP&lt;5.If they meet all criteria,  the ventilator settings are set as follows: Mode: Spont/PSV, PEEP≤5, FiO2≤40, PS according to ET size (3-3.5:10, 4-4.5:8, ≥5:6). The SBT failure is confirmed in case at least two of the following conditions are observed during the intervention: respiratory rate being outside the normal range by age, i.e. tachypnea or bradypnea, respiratory distress, VTe&lt;5 ml/kg, SatO2&lt;90%, hypotension based on PALS guidelines or an over 20% increase in blood pressure, impaired consciousness associated with hypoventilation, heart rate outside the normal range by age, i.e. tachycardia and bradycardia, Pco2&gt;55 mmHg or an increase in Pco2 by at least 10mmHg in patients with chronic pulmonary disease in the final arterial-blood gas test. If the test failed, the parameters and mode of the ventilator are set as before the test, and if the clinical criteria are met as described, the test is repeated 24 hours later.Endotracheal  tube is immediately extracted if the test is successful, and the patient is provided with a non-rebreathing face mask with a 10-15 l/min flow, and undergo100% oxygen therapy. Arterial-blood gas test is performed two hours after extubation. Extubation failure is confirmed in case at least two of the following symptoms emerged within two days of extubation: respiratory distress, hypoxia with SatO2&lt;90%, respiratory rate outside the normal range by age, i.e. tachypnea or bradypnea , apnea&gt;20 seconds, hypotension based on PALS guidelines or an over 20% increase in blood pressure, impaired consciousness associated with hypoventilation, heart rate outside the normal range by age, i.e. tachycardia and bradycardia, Pco2&gt;55 mmHg or an increase in Pco2 by at least 10mmHg in patients with chronic pulmonary disease accompanied by PH&lt;7.3 and symptoms of upper airway obstruction. In case of the absence of contraindications for NIMV, Bi-level positive airway pressure (BiPAP) is applied with minimum settings as EPAP:5 and IPAP:8-10, and tittered up to EPAP:8-10 and IPAP:5-22 and until clinical and laboratory symptoms of respiratory failure disappear. The patient is reintubated if respiratory failure symptoms persist after two hours of monitoring</i_keyword>
      <i_keyword>In control group ,The attendant of pediatric or anesthesiology by ICU fellowship decides on ventilator settings and respiratory support reduction and extubation according to the results of arterial-blood gas tests performed at least once a day and based on the patient's clinical conditions, including eliminating the causes of intubation, appropriate ventilation and oxygenation and stable vital signs.The post-extubation oxygen supply method, the criteria of extubation failure and NIMV and reintubation protocols are as same as the intervention group.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Mechanical ventilation duration. Timepoint: 9 months. Method of measurement: Hospital admission file.</prim_outcome>
      <prim_outcome>Extubation failure. Timepoint: 9 months. Method of measurement: Hospital admission file.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Length of hospital stay. Timepoint: 9 months. Method of measurement: Hospital admission file.</sec_outcome>
      <sec_outcome>Length of PICU stay. Timepoint: 9 months. Method of measurement: Hospital admission file.</sec_outcome>
      <sec_outcome>Mortality in PICU. Timepoint: 9 months. Method of measurement: Hospital admission file.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Esfahan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-02-03</approval_date>
        <contact_name>Ethics committee of Isfahan university of medical sciences</contact_name>
        <contact_address>Hezarjerib Avenue Isfahan Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
